PointState Capital’s AbbVie ABBV Stock Holding History

PointState Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-150,000	Closed	-$16.9M	–	138
2021 Q2	$16.9M	Buy	+150,000	New	+$16.9M	0.29%	64

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PointState Capital's ABBV Position: Q3 2022 in Review

PointState Capital sold out of AbbVie (ABBV) in Q3 2022, closing a stake of 39,047 shares — an estimated $5.98M sold.

PointState Capital first reported a position in ABBV in Q2 2013 and held it in 13 quarters. The position peaked at $437M in Q3 2014. 2,969 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

PointState Capital reported no remaining AbbVie position as of Q3 2022 after selling out during the quarter.
PointState Capital sold 39,047 AbbVie shares in Q3 2022, an estimated $5.98M.
PointState Capital first reported a position in AbbVie in Q2 2013 and held it in 13 quarters.
PointState Capital's AbbVie position peaked at $437M in Q3 2014.
2,969 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on PointState Capital's 13F filing for Q3 2022, filed 10 Nov 2022.